Trial Profile
A Double-blind, Randomized, Placebo-controlled Phase 3 Study of Orally Administered PLX3397 in Subjects with Pigmented Villonodular Synovitis or Giant Cell Tumor of the Tendon Sheath ENLIVEN
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 20 Feb 2024
Price :
$35
*
At a glance
- Drugs Pexidartinib (Primary)
- Indications Giant cell tumour of tendon sheath; Pigmented villonodular synovitis
- Focus Registrational; Therapeutic Use
- Acronyms ENLIVEN; PLX108-10
- Sponsors Daiichi Sankyo Inc
- 04 Jun 2021 This trial has been completed in Hungary, according to European Clinical Trials Database record.
- 01 Jun 2021 Status changed from active, no longer recruiting to completed.
- 11 Jan 2021 Planned End Date changed from 1 Mar 2021 to 30 Apr 2021.